Results 101 to 110 of about 102,703 (336)

A Systemic Selective Modified mRNA Delivery Platform for Preventing Chemotherapy‐Induced Cardiotoxicity

open access: yesAdvanced Science, EarlyView.
In Yoo and Mainkar et al., we present a minimally invasive, CM‐selective modRNA delivery system encapsulated in lipid nanoparticles for intravenous (IV) administration. This platform enables selective cardiac translation of therapeutic modRNA but suppresses expression in off‐target tissues, including tumors.
Jimeen Yoo   +19 more
wiley   +1 more source

Follow-up after curative resection for gastric cancer. Is it time to tailor it? [PDF]

open access: yes, 2017
There is still no consensus on the follow-up frequency and regimen after curative resection for gastric cancer. Moreover, controversy exists regarding the utility of follow-up in improving survival, and the recommendations of experts and societies vary ...
Antolino, L   +5 more
core   +1 more source

A systematic review on quality of life (QoL) of patients with peritoneal metastasis (PM) who underwent pressurized intraperitoneal aerosol chemotherapy (PIPAC)

open access: diamond, 2022
Zhenyue Li   +8 more
openalex   +1 more source

Targeting NRP1 in Endothelial Cells Facilitates the Normalization of Scar Vessels and Prevents Fibrotic Scarring

open access: yesAdvanced Science, EarlyView.
Scars exhibit vascular abnormal alterations, including upregulated NRP1 expression in endothelial cells, increased vascular density and branching, compromised vessel wall integrity, and incomplete pericyte coverage. Therapeutic targeting of NRP1 through hydrogel spray delivery offers a promising approach to normalize aberrant vasculature and prevent ...
Yu Wang   +11 more
wiley   +1 more source

Effect of hyperthermia on improving neutrophil restoration after intraperitoneal chemotherapy

open access: yesInternational Journal of Hyperthermia, 2019
Purpose: Intraperitoneal (IP) chemotherapy has several benefits but also can have severe hematologic side effects. We compared the effects of hyperthermic intraperitoneal chemotherapy (HIPEC) and conventional IP chemotherapy on bone marrow suppression ...
Wan-Chun Huang   +3 more
doaj   +1 more source

Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. [PDF]

open access: yes, 2018
Expression of the chromatin-associated protein HMGA2 correlates with progression, metastasis and therapy resistance in pancreatic ductal adenocarcinoma (PDAC). Hmga2 has also been identified as a marker of a transient subpopulation of PDAC cells that has
Chiou, Shin-Heng   +7 more
core   +1 more source

PARPi Combining Nanoparticle LIN28B siRNA for the Management of Malignant Ascites

open access: yesAdvanced Science, EarlyView.
This study demonstrates that co‐inhibition of LIN28B and PARP using siLin28b/DSSP@lip‐PEG‐FA nanoparticles in combination with the PARP inhibitor BMN673 effectively suppresses the accumulation of malignant ascites associated with advanced cancers.
Yan Fang   +13 more
wiley   +1 more source

ACSL5 Regulates Glucose Metabolism and Chemotherapy Sensitivity in Colorectal Cancer Cells under Glutamine Deficiency

open access: yesAdvanced Science, EarlyView.
Glutamine deprivation triggers ACSL5 upregulation in tumor cells, sustaining their viability via dual metabolic rewiring programs. ACSL5 enhances glycolysis by relieving p53's inhibition of PGAM1 while also sustaining mitochondrial respiration and TCA cycle flux through promoting IDH2 dimerization.
Shuai Tian   +11 more
wiley   +1 more source

LMO7 Suppresses Tumor‐Associated Macrophage Phagocytosis of Tumor Cells Through Degradation of LRP1

open access: yesAdvanced Science, EarlyView.
LMO7 in tumor‐associated macrophages suppresses phagocytosis of tumor cells and limits cytotoxic T lymphocytes infiltration, fostering tumor progression. Mechanistically, LMO7 mediates the ubiquitination and degradation of the phagocytic receptor LRP1, impairing its ability to engulf tumor cells and driving macrophages toward an antitumor phenotype ...
Mengkai Li   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy